High-dose proton beam therapy for sinonasal mucosal malignant melanoma

被引:43
|
作者
Fuji, Hiroshi [1 ,7 ]
Yoshikawa, Shusuke [2 ]
Kasami, Masako [3 ]
Murayama, Shigeyuki [1 ]
Onitsuka, Tetsuro [4 ,5 ]
Kashiwagi, Hiroya [6 ]
Kiyohara, Yoshio [2 ]
机构
[1] Shizuoka Canc Ctr Hosp, Div Proton Therapy, Shizuoka 4118777, Japan
[2] Shizuoka Canc Ctr Hosp, Div Dermatol, Shizuoka 4118777, Japan
[3] Shizuoka Canc Ctr Hosp, Div Pathl, Shizuoka 4118777, Japan
[4] Shizuoka Canc Ctr Hosp, Div Head Surg, Shizuoka 4118777, Japan
[5] Shizuoka Canc Ctr Hosp, Div Neck Surg, Shizuoka 4118777, Japan
[6] Shizuoka Canc Ctr Hosp, Div Opthalomol, Shizuoka 4118777, Japan
[7] Natl Ctr Child Hlth & Dev, Div Radiat Oncol, Setagaya Ku, Tokyo 1578535, Japan
关键词
Mucosal melanoma; Proton beam therapy; Radiotherapy; Sinonasal melanoma; NASAL CAVITY; HEAD; RADIOTHERAPY; NECK;
D O I
10.1186/1748-717X-9-162
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The significance of definitive radiotherapy for sinonasal mucosal melanoma (SMM) is sill controvertial. This study was to evaluate the role of high-dose proton beam therapy (PBT) in patients with SMM. Methods: The cases of 20 patients with SMM localized to the primary site who were treated by PBT between 2006 and 2012 were retrospectively analyzed. The patterns of overall survival and morbidity were assessed. Results: The median follow-up time was 35 months (range, 6-77 months). The 5-year overall and disease-free survival rates were 51% and 38%, respectively. Four patients showed local failure, 2 showed regrowth of the primary tumor, and 2 showed new sinonasal tumors beyond the primary site. The 5-year local control rate after PBT was 62%. Nodal and distant failure was seen in 7 patients. Three grade 4 late toxicities were observed in tumor-involved optic nerve. Conclusion: Our findings suggested that high-dose PBT is an effective local treatment that is less invasive than surgery but with comparable outcomes.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy
    Tulay Akman
    Ilhan Oztop
    Yasemin Baskin
    Mahdi Akbarpour
    Olcun Umit Unal
    Utku Oflazoglu
    Hulya Ellidokuz
    Medical Oncology, 2015, 32
  • [32] The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy
    Akman, Tulay
    Oztop, Ilhan
    Baskin, Yasemin
    Akbarpour, Mahdi
    Unal, Olcun Umit
    Oflazoglu, Utku
    Ellidokuz, Hulya
    MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 10
  • [33] High-dose proton beam therapy for stage I non-small-cell lung cancer
    Nihei, K
    Ogino, T
    Ishikura, S
    Nishimura, H
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (01): : 107 - 111
  • [34] PROTON BEAM THERAPY AS A NONSURGICAL APPROACH TO MUCOSAL MELANOMA OF THE HEAD AND NECK: A PILOT STUDY
    Zenda, Sadamoto
    Kawashima, Mitsuhiko
    Nishio, Teiji
    Kohno, Ryosuke
    Nihei, Keiji
    Onozawa, Masakatsu
    Arahira, Satoko
    Ogino, Takashi
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (01): : 135 - 139
  • [35] High-Dose Proton Beam Boosted Radiation Therapy in the Management of Non-Skull Base Chondrosarcomas
    Bhatt, A. D.
    Jacobson, A.
    Lee, R. Y.
    Giraud, C.
    Schwab, J.
    Hornicek, F.
    Nielsen, P.
    Choy, E.
    Harmon, D.
    DeLaney, T. F.
    Chen, Y. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S766 - S767
  • [36] Adjuvant interferon therapy for melanoma: High-dose, low-dose, no dose, which dose?
    Schuchter, LM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) : 7 - 10
  • [37] High-dose therapy in malignant lymphomas. The status quo
    Schmitz, N.
    Nickelsen, M.
    Sureda, A.
    ONKOLOGE, 2007, 13 (05): : 425 - +
  • [38] HIGH DOSE METHOTREXATE THERAPY FOR DISSEMINATED MALIGNANT-MELANOMA
    EILBER, FR
    ISAKOFF, W
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1976, 17 (MAR): : 262 - 262
  • [40] Proton Beam Therapy of Iris Melanoma
    Willerding, G. D.
    Cordini, D.
    Moser, L.
    Bechrakis, N. E.
    Foerster, M. H.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)